Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Executive Decision: Patient Safety & Transparency Over Short-Term Gain Core Strategy: I will not wait. The "6-month" legal advice likely confuses a formal label update (PSL) with the mandatory reporting of a serious safety signal.Read the full answer
As CEO, my overriding duty is to balance patient safety, legal/regulatory compliance, fiduciary responsibility, and long-term corporate survival. A 1-in-8,000 risk of liver failure is rare but severe, potentially fatal, and materially unexpected relative to the current label.Read the full answer